LIVE WEBINAR 27/01 | Targeted Alpha Therapy: Navigating the Path to Clinical Implementation and Future Outlook
With Prof Dr Frederik Giesel and Prof Dr Hugo Levillain
Take part in this interesting webinar on alpha therapies in the field of nuclear medicine, with Prof Dr Frederik Giesel and Prof Dr Hugo Levillain.
Throughout this webinar, our esteemed speakers will explore the scientific principles, discuss the latest advancements in radiopharmaceutical development and highlight key clinical trials involving Actinium-225, showcasing its potential in treating cancers such as prostate cancer.
We will also discuss the early and upcoming trials with Astatine-211. Additionally, our speakers will address the challenges and future directions in this exciting field.
Register now and don't miss out on this opportunity to ask your questions to Prof Dr Giesel and Prof Dr Levillain.
Duration: 20' by session followed by a live Q&A session
Prof Dr Frederik Giesel is Chairman of the Nuclear Medicine Department at the University Hospital Düsseldorf in Germany.
Alongside, he is visiting Professor at the Osaka University in Japan.
Also, he had visiting professorships in renowned Universities such as Stanford University, USA and Yonsei University, South Korea
Prof Dr Hugo Levillain is a medical physicist and Head of R&D in the Department of Medical Physics at the Brussels University Hospital, where he collaborates with renowned experts like Prof Dr Patrick Flamen, Head of Nuclear Medicine Department of Institut Jules Bordet.
He is also Professor at the Faculty of Medicine of ULB, co-director of the Laboratory of Medical Radiophysics and MRI Physics, Director of the nuMix cluster, The Center for Microscopy and Molecular Imaging (CMMI).